MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
暂无分享，去创建一个
A. Drilon | R. Camidge | R. Doebele | V. Velcheti | S. Kao | M. Krebs | C. Baik | M. Nagasaka | Jessica J. Lin | B. Cho | B. Solomon | K. Lee | V. Zhu | S. Stopatschinskaja | A. Wekken | Shan Liu | A. J. van der Wekken